Infectious Diseases

The FDA approved ensitrelvir (Xocova) for post-exposure prophylaxis of COVID-19 in adults and adolescents aged 12 years and older following contact with an individual with COVID-19.

In a phase 3 trial, ensitrelvir reduced symptomatic COVID-19 after household exposure when started within 72 hours.

Recent studies in children and adults associate long COVID with worsened academic performance, attention difficulties, subjective cognitive impairment, and persistent neurologic and psychiatric symptoms. ...

The FDA approved a once-daily, 2-drug oral regimen for adults with virologically suppressed HIV-1 to replace existing antiretroviral therapy.

New reports detail the spread of SARS-CoV-2 variant BA.3.2, Long COVID disability burden, sarbecovirus cross-immunity, and how stacked outpatient risk factors shape severe COVID-19 outcomes.

In a phase 3b trial, monthly dapivirine ring and daily oral PrEP were assessed for safety, adherence, and acceptability in pregnancy.

New reports link SARS-CoV-2 and RSV to persistent cardiopulmonary risk and describe distinct postviral lung and brain changes in a mouse model.

This roundup explores updated 2024-2025 COVID-19 vaccine effectiveness data, an FDA-cleared 4-pathogen home test, and new evidence on metformin for long COVID risk.

A large multinational cohort study evaluated whether COVID-19 vaccination during pregnancy reduces the risk of preeclampsia, a major hypertensive complication associated with SARS-CoV-2 infection.

In the phase 3 ACTG A5359 LATITUDE trial, investigators evaluated whether monthly, long-acting injectable cabotegravir plus rilpivirine could reduce regimen failure compared with standard oral...